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basis of the current knowledge, mTOR could play a role in
the pathogenesis of both adrenocortical carcinomas and 
pheochromocytomas. Moreover, mTOR inhibitors, interfer-
ing with the activation of several mitogenic and angiogenic 
factors, could be considered as a novel treatment opportu-
nity for the management of malignant adrenal tumors. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Adrenal tumors include benign and malignant corti-
cal tumors and benign and malignant pheochromocyto-
mas  [1] . The malignant adrenal tumors are aggressive tu-
mors with a poor prognosis  [2–5] . The surgical removal 
of the tumor represents the treatment of choice for both 
benign and malignant hormone-secreting tumors, for all 
tumors suspected to be a pheochromocytoma, as well as 
for all non-hormone-secreting adrenal masses with clin-
ical and radiological suspicion of malignancy  [1, 2, 6] . 
However, in malignant tumors, surgery allows a complete 
remission only in a minority of cases with a diagnosis in 
the early stage of the disease  [3, 4, 6] . The role of medical 
treatment in benign adrenocortical tumors is generally 
restricted to the treatment of the symptoms related to the 
hormonal hypersecretion using drugs interfering with 
the hormonal production and/or the hormonal actions 
(i.e. spironolactone, adrenolytic agents), in the time pre-
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 Abstract 
 The mammalian target of rapamycin (mTOR) is a kinase of the 
phosphoinositide 3-kinase (PI3Ks)/protein kinase B (PKB or 
AKT) signaling pathway, which is one of the most important 
intracellular mediators of the activity of growth factors re-
ceptors, including vascular endothelial growth factor (VEGF) 
and insulin-like growth factors (IGFs). Dysregulation of the 
mTOR pathway has been found in many human tumors. 
Therefore, the mTOR pathway is considered as a target for 
antineoplastic therapy in several malignancies. Presently, 
the role and functions of mTOR and its signaling pathway in 
the normal and pathological adrenal gland has not been 
clarified yet. However, many growth factors and growth fac-
tor receptors, which are considered to play a role in the 
pathogenesis of adrenal tumors, can at least in part exert 
their effects through the activation of PI3K/AKT/mTOR path-
way. Dysregulation of AKT has been reported in adrenocorti-
cal carcinomas and adrenomedullary tumors, named pheo-
chromocytomas. Adrenocortical carcinomas and malignant 
pheochromocytomas are aggressive tumors with poor
prognosis and scant treatment options. Therefore, new treat-
ment options are warranted for these malignancies. On the 
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ceding the surgery. In adrenocortical carcinomas, the 
medical treatment with traditional cytotoxic chemother-
apy is not satisfactory  [5, 6] . Mitotane, the most common-
ly used adrenolytic agent, is able to control the hormonal 
hypersecretion in the majority of patients with hormone-
secreting adrenocortical carcinomas, but has been asso-
ciated with an objective tumor regression only in about 
25% of cases  [6] . In patients with pheochromocytomas 
anti-adrenergic agents (i.e.   -adrenergic blockers) are 
used for the symptomatic treatment in the time preced-
ing the surgery and to reduce the risks of adrenergic crisis 
during the surgery. In patients with inoperable malignant 
pheochromocytomas, besides the symptomatic treat-
ment with antiadrenergic agents, radionuclide thera -
py with  131 I-metaiodobenzylguanidine and combination 
chemotherapy, have been used. However, the results ob-
tained with these treatments are still disappointing  [3,
4, 7] .
 The limited efficacy of conventional antineoplastic 
treatment in malignant adrenal tumors increases the 
need for novel, more effective treatment options. In re-
cent years, the progress in understanding of the patho-
genesis of tumors is encouraging and has initiated the 
development of the so-called ‘targeted drugs’, compounds 
that specifically interfere with molecular mechanisms in-
volved in tumor cell growth and/or tumor vascular sup-
ply. Included in this category of drugs are compounds 
interfering with growth factor receptors (including pro-
angiogenesis factors) and their related signaling path-
ways. Alterations of growth factors and their cognate
receptors have been considered to be involved in the 
pathogenesis of both adrenocortical cancers and pheo-
chromocytomas  [7–9] . Moreover, tumor angiogenesis is 
essential for the growth and progression of solid tumors, 
including adrenal tumors  [7, 8, 10, 11] . Therefore, com-
pounds interfering with tumor angiogenesis and growth 
factor signaling pathways represent a potential novel 
treatment opportunity for the management of malignant 
adrenal tumors. 
 mTOR Pathway 
 The mammalian target of rapamycin (mTOR) is a pro-
tein kinase of the phosphoinositide 3-kinase (PI3Ks)/
protein kinase B (PKB or AKT) signaling pathway, that 
forms multimolecular intracellular complexes and func-
tions as a gatekeeper of metabolism as well as cell growth, 
receiving signals from sensors of cell stress, intracellular 
nutrients levels and several growth factors, including vas-
cular endothelial growth factor (VEGF), insulin-like 
growth factors (IGFs), epidermal growth factor (EGF) 
and platelet-derived growth factor (PDGF)  [12–15] . The 
complexes formed by mTOR are named mTORC1 and 
mTORC2, and are sensitive or insensitive to rapamycin, 
respectively, the oldest compound among the mTOR in-
hibitors  [16] . The binding of many growth factors to their 
cognate receptor tyrosine kinases (RTKs) leads to the
recruitment of PI3K to the membrane, where this en-
zyme converts phosphatidylinositol bisphosphate (PIP2) 
to phosphatidylinositol trisphosphate (PIP3), providing 
docking sites for signaling proteins, including 3-phos-
phoinositide-dependent protein kinase 1 (PDK1) and the 
serine-threonine kinase AKT. These events are antago-
nized by PTEN (phosphatase and tensin homologue) that 
limits the growth factor signaling by dephosphorylating 
PIP3.  Figure 1 shows a simplified scheme of growth fac-
tor-induced activation of the mTOR pathway and the 
sites of action of compounds acting as mTOR inhibitors. 
PDK1 is a serine-threonine kinase that phosphorylates 
and activates AKT, which elicits many downstream sig-
naling events including the activation of mTORC1. AKT 
promotes mTORC1 activity mainly by phosphorylating 
the tuberosus-sclerosis complex (TSC1/2)  [16, 17] . This 
phosphorylation leads to the inactivation of TSC2 that is 
an indirect inhibitor of mTORC1 and results in the acti-
vation of this complex  [16] . mTOR as part of mTORC1 
complex can also be directly phosphorylated by AKT, 
forming phospho-mTOR (p-mTOR), that is often stud-
ied as a marker of mTOR activation. However, whether 
this phosphorylation is crucial or not in the activation of
the mTORC1 complex is still a matter of discussion  [16, 
17] . Activation of the mTORC1 complex leads to the 
phosphorylation and activation of downstream effectors 
of the pathway: the protein kinase p70 ribosomal protein 
S6 kinase 1 (S6K1) and eukaryotic translation initiation 
factor 4E-binding proteins (4EBP1)  [16] . S6K1 and 4EBP1 
are both regulators of mRNA translation and stimulate 
the synthesis of several oncogenic proteins such us c-Myc, 
hypoxia-inducible factor-1  (HIF-1  ), VEGF, IGF-II and 
cyclin D  [13] . Conversely, mTORC2 regulates the cyto-
skeleton function and it has been proposed to be an im-
portant activator of the AKT function. Growth factors 
stimulate mTORC2, activity and some components of 
mTORC2 complex are phosphorylated as consequences 
of growth factor stimulation, but the responsible kinases 
are uncertain  [16] . Therefore, there is evidence that mTOR 
as part of both complexes (mTORC1 and mTORC2) me-
diates the intracellular signaling induced by growth fac-
tor receptor activation ( fig.  1 ). However, mTORC1 is 
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downstream to AKT and mTORC2 seems to be upstream 
to AKT  [13, 16] .
 It is noteworthy that mTOR is an intracellular media-
tor of IGFII and VEGF activity and, in turn, is able to 
control the synthesis of these growth factors  [13] . VEGF 
is one of the most important mediators of angiogenesis in 
solid tumors including adrenal tumors. Moreover, growth 
factors such as IGFs and VEGF are autocrine/paracrine 
regulators of tumoral cell growth in many different types 
of tumors, including adrenal tumors ( fig. 2 )  [8–11, 18] . 
Dysregulation of the mTOR pathway has been found in 
many human tumors, including neuroendocrine tumors 
 [13, 14, 19, 20] . Therefore, the mTOR pathway is consid-
ered an important target for antineoplastic therapies and 
it is conceivable that it could also play a role in the patho-
genesis of adrenal tumors. mTOR inhibitors may exert 
their antitumor effects indirectly, by inhibiting tumor 
angiogenesis, and directly by inhibiting cell growth and 
proliferation  [16] . It is conceivable that mTOR inhibitors, 
interfering with several mitogenic and angiogenic fac-
tors, could inhibit adrenal tumor growth. 
 Presently, many clinical trials (phase I–III) are inves-
tigating the antineoplastic effects of mTOR inhibitors, 
mainly targeting the mTORC1 complex (shown in  fig. 1 
as ‘traditional’ mTOR inhibitors), such as sirolimus (rap-
amycin), temsirolimus (CCI-779), everolimus (RAD001) 
and deforolimus (AP23573), alone or in combination 
with other compounds, in several kinds of solid tumors 
and hematological malignancies. On the basis of the clin-
ical studies already concluded, a safe schedule of treat-
ment has been defined for each of these compounds
and promising results of antitumor activity have been 
achieved in a variety of malignancies, and some of these 
compounds are already approved for the treatment of ad-
vanced renal cell carcinoma  [13, 14, 17, 19] . 
 The activity of mTORC2 is not directly inhibited by the 
above-listed compounds, but it has been reported that 
long-term treatment with rapamycin can inhibit the activ-
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ity of mTORC2 by the sequestering of mTOR as part of the 
mTORC1 complex  [13] . However, new compounds, able to 
directly inhibit both mTORC complexes such us AZD8055 
and OSI-027 (reported in  fig. 1 as ‘new’ mTOR inhibitors) 
are proceeding in the early clinical testing  [17] . The results 
of these studies will answer the question whether the use 
of compounds blocking both mTORC complexes could 
have additional advantage over the use of traditional 
mTOR inhibitors in the treatment of tumors.
 To the best of our knowledge, there are no preclinical 
or clinical studies evaluating the effects of mTOR inhibi-
tor drugs in adrenocortical tumors and only very limited 
data in pheochromocytomas  [20–22] .
 Role of the mTOR Pathway in Normal Adrenal Gland 
 Up to our knowledge, there are no studies evaluating 
the mTOR pathway in the normal adrenal gland. The ex-
pression of mTOR, p-mTOR, AKT and phospho-AKT (p-
AKT) in the normal adrenal gland has been evaluated 
only as a control for adrenal tumors  [20, 23] . In 3 out of 3 
normal adrenals, no staining for p-mTOR and p-AKT, 
evaluated by immunohistochemistry, has been reported 
in the normal adrenal medullas  [23] . Fassnacht et al.  [20] 
have evaluated the expression of total-AKT and p-AKT 
in 4 normal adrenal glands by immunohistochemistry. 
They described a notable staining for total-AKT and p-
AKT in the reticularis layer, whereas a weaker expression 
of total- and p-AKT was found in the fasciculata and glo-
merulosa and only a faint staining for total-AKT in the 
normal medulla. These preliminary observations suggest 
that there is a layer-specific pattern of activation of the 
PI3Ks/AKT/mTOR pathway in the normal adrenal gland, 
which seems to be predominantly inactive in the normal 
adrenal medulla and active in the reticularis layer of the 
adrenal cortex. IGFs have been reported to stimulate ad-
renal steroidogenesis, particularly androgen production 
 [18] . The activation of PI3K/AKT/mTOR pathway in the 
reticularis of normal adrenals suggests a potential role of 
this pathway in the control of androgen production, 
probably as intracellular mediator of the IGFs.
 Potential Role of the mTOR Pathway in Adrenal 
Tumors 
 Presently, the role and function of mTOR and its path-
way in adrenal tumors have not yet been clarified. How-
ever, total-AKT has been found to be overexpressed both 
in adrenocortical carcinomas and in pheochromocyto-
mas, compared to normal adrenals or adenomas  [20] . The 
corresponding activated form, p-AKT, has also been re-
ported to be overexpressed in pheochromocytomas  [20, 
24] . Equivocal data exist with the respect to p-AKT ex-
pression in adrenocortical carcinomas  [20, 25] . Indeed, 
some authors report overexpression of p-AKT in adreno-
cortical carcinomas  [25] , while others do not  [20] . Mice 
with a heterozygous deletion of the PTEN gene present 
an increased tendency to develop pheochromocytomas 
 [26] . However, PTEN mutations appear to be rare in hu-
man pheochromocytomas  [27, 28] , suggesting that in hu-
man pheochromocytomas the mechanisms involved in 
the overactivation of p-AKT are different from mice.
 In H295 and SW13, two different human adrenocorti-
cal carcinoma cell lines  [25, 29] , and in PC12, a rat pheo-
chromocytoma cell line  [30] , IGF-I stimulation has been 
correlated with increased AKT phosphorylation, sug-
gesting that AKT is one of the intracellular mediators of 
IGF signaling in adrenal tumors. In PC12 cells, the effects 
of some growth factors on downstream components of 
the mTOR pathway have also been evaluated. EGF and 
nerve growth factor (NGF) were reported to stimulate the 
phosphorylation of 4EBP1  [31] and EGF has also been 
shown to increase the phosphorylation of S6K1  [32] . 
These effects were prevented by the administration of
rapamycin  [32] .
 As indicated above, it has been shown that mTOR can 
stimulate the translation of IGF-II and VEGF. In turn, 
this stimulation can be induced by the same growth fac-
tors  [13] . Therefore, mTOR could be one of the intracel-
lular mediators of the pro-survival/pro-growth effects of 
growth factor signaling in adrenal tumors and it could be 
an intracellular component to the pro-growth autocrine 
loops and pro-angiogenetic events, considered to be in-
volved in the pathogenesis of adrenal tumors, as shown 
in  figure 2 . 
 Role of mTOR as a Drug Target in the Treatment of 
Adrenal Tumors 
 To the best of our knowledge, there are no clinical or 
preclinical published data evaluating the effects of mTOR 
inhibitors in adrenocortical carcinomas. However, com-
pounds blocking IGF-I receptor activity have been found 
to inhibit the proliferation of H295 cells  [25, 33] . These 
effects have been correlated with a reduction of p-AKT 
 [25] , suggesting that AKT itself and/or mTOR could be
a potential target for the treatment of adrenocortical car-
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cinomas. Inhibition of the IGF-I receptor in preclinical 
models of human adrenocortical carcinomas has been as-
sociated with a reduction of VEGF production  [25] . Ac-
cording with the described role of mTOR in VEGF pro-
duction  [13] , it is conceivable that the inhibition of VEGF 
induced by the IGF-I receptor inhibitors is related to the 
inhibition of the mTOR pathway. LY294002, an AKT in-
hibitor, has been found to inhibit proliferation of PC12 
cells in a time- and dose-dependent manner  [24] . In neu-
roblastoma cell lines (a tumor closely related to pheo-
chromocytoma), rapamycin inhibits cell proliferation by 
inducing cell cycle arrest  [34] . Rapamycin, evaluated as a 
single dosage, has been found to significantly inhibit cell 
growth in the normal chromaffin rat cells, but not in the 
PC12 cell line  [22] . In a recent study evaluating the effects 
of glucacon-like-peptide-1 (GLP-1) in PC12 cells, used as 
a model for neuronal cells, the authors show that GLP-1, 
through the activation of PI3K/AKT/mTOR pathway, is 
able to protect these cells from oxidative stress-induced 
cell apoptosis  [35] . These protective effects were inhibited 
by the treatment with rapamycin. In an animal model for 
pheochromocytoma, temsirolimus was able to inhibit tu-
mor progression  [26] . This effect could either be attrib-
uted to a direct effect of the mTOR inhibitor on tumoral 
cell proliferation or to the inhibitory effects of temsiroli-
mus on vascular growth. Therefore, further preclinical 
studies should be performed to clarify whether these 
compounds might have a direct effect on pheochromo-
cytoma cells, whether these effects could depend on the 
presence of growth factors in the cell environment, and 
whether the combination treatment using mTOR inhibi-
tors and other compounds, such us conventional chemo-
therapics or other targeted drugs (i.e. IGF-I receptor an-
tagonists), could have stronger antineoplastic effects than 
the monotherapy. The promising effects of mTOR inhib-
itors in the treatment of neuroendocrine tumors  [36, 37] 
IGFs/insulin 
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mTOR
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Angiogenesis
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CELLS Fig. 2. Potential role of the mTOR pathway 
in adrenal tumors. 
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